Where Will Planet Labs Stock Be in 3 Years?
Planet Labs is far from a typical satellite-imager company. Founded…
Sell
8
NVNO Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
5.52%
Day range:
$0.74 - $0.80
52-week range:
$0.76 - $5.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
473.07x
P/B ratio:
0.45x
Volume:
818K
Avg. volume:
1.5M
1-year change:
-85.38%
Market cap:
$14.9M
Revenue:
--
EPS (TTM):
-$1.20
Analysts' Opinion
-
Consensus RatingenVVeno Medical Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.50, enVVeno Medical Corp. has an estimated upside of 1517.29% from its current price of $0.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.50 representing 100% downside risk from its current price of $0.76.
Fair Value
-
According to the consensus of 1 analyst, enVVeno Medical Corp. has 1517.29% upside to fair value with a price target of $12.50 per share.
NVNO vs. S&P 500
-
Over the past 5 trading days, enVVeno Medical Corp. has underperformed the S&P 500 by -11.47% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
enVVeno Medical Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
enVVeno Medical Corp. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter enVVeno Medical Corp. reported revenues of --.
Earnings Growth
-
enVVeno Medical Corp. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter enVVeno Medical Corp. reported earnings per share of -$0.33.
Enterprise value:
-19.4M
EV / Invested capital:
-0.57x
Price / LTM sales:
473.07x
EV / EBIT:
--
EV / Revenue:
283.88x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
1.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$503K
Return On Assets:
-54.03%
Net Income Margin (TTM):
--
Return On Equity:
-57.87%
Return On Invested Capital:
-56.37%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$537K | -$549K | -$503K | -$136K | -$130K | |
| Operating Income | -$26.2M | -$22.6M | -$24.9M | -$5.5M | -$7M | |
| EBITDA | -$25.7M | -$22M | -$24.4M | -$5.3M | -$6.9M | |
| Diluted EPS | -$2.24 | -$1.39 | -$1.20 | -$0.31 | -$0.33 | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $41.4M | $37.8M | $30.1M | $39.5M | $35.6M | |
| Total Assets | $42.4M | $49.9M | $32.1M | $41M | $36.6M | |
| Current Liabilities | $1.4M | $1.8M | $2.1M | $1.7M | $3M | |
| Total Liabilities | $1.5M | $3.4M | $3.3M | $2.6M | $3.5M | |
| Total Equity | $40.9M | $46.6M | $28.8M | $38.4M | $33.1M | |
| Total Debt | -- | $1.9M | $1.6M | $1.2M | $882K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-06-30 | 2024-06-30 | 2025-06-30 | 2024-06-30 | 2025-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18M | -$16.6M | -$17.1M | -$3.9M | -$3.7M | |
| Cash From Investing | $13.7M | -$11.5M | $3.2M | $4M | $2.8M | |
| Cash From Financing | -- | $25.8M | $13.6M | -- | -- | |
| Free Cash Flow | -$18.1M | -$16.7M | -$17.1M | -$3.9M | -$3.7M | |
NVNO
Sector
Market Cap
$14.9M
$32.4M
Price % of 52-Week High
13.56%
49.8%
Dividend Yield
0%
0%
Shareholder Yield
-17.58%
-1.37%
1-Year Price Total Return
-85.02%
-23.68%
Beta (5-Year)
0.871
0.574
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.81
200-day SMA
Sell
Level
$3.32
Bollinger Bands (100)
Sell
Level
2.35 - 4.83
Chaikin Money Flow
Sell
Level
-26.1M
20-day SMA
Sell
Level
$2.19
Relative Strength Index (RSI14)
Sell
Level
17.89
ADX Line
Sell
Level
60.89
Williams %R
Buy
Level
-99.7505
50-day SMA
Sell
Level
$3.61
MACD (12, 26)
Sell
Level
-0.54
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Sell
Level
-24.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.0019)
Sell
CA Score
(Annual)
Level (-0.7222)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (13.0505)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.
Stock Forecast FAQ
In the current month, NVNO has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NVNO average analyst price target in the past 3 months is $12.50.
-
Where Will enVVeno Medical Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that enVVeno Medical Corp. share price will rise to $12.50 per share over the next 12 months.
-
What Do Analysts Say About enVVeno Medical Corp.?
Analysts are divided on their view about enVVeno Medical Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that enVVeno Medical Corp. is a Sell and believe this share price will drop from its current level to $12.50.
-
What Is enVVeno Medical Corp.'s Price Target?
The price target for enVVeno Medical Corp. over the next 1-year time period is forecast to be $12.50 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NVNO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for enVVeno Medical Corp. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of NVNO?
You can purchase shares of enVVeno Medical Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase enVVeno Medical Corp. shares.
-
What Is The enVVeno Medical Corp. Share Price Today?
enVVeno Medical Corp. was last trading at $0.72 per share. This represents the most recent stock quote for enVVeno Medical Corp.. Yesterday, enVVeno Medical Corp. closed at $0.76 per share.
-
How To Buy enVVeno Medical Corp. Stock Online?
In order to purchase enVVeno Medical Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CRM’s Share Buyback a Buy Signal?
CRM software giant Salesforce (NYSE:CRM) has been vigorously buying back…
Is Lululemon Stock on Sale?
Picture this, you’re in your favorite yoga studio, stretching into…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 57x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 36x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Alerts
Buy
84
OCTO alert for Sep 9
Eightco Holdings, Inc. [OCTO] is down 26.31% over the past day.
Sell
34
GGAL alert for Sep 9
Grupo Financiero Galicia SA [GGAL] is up 2.38% over the past day.
Sell
13
BMA alert for Sep 9
Banco Macro SA [BMA] is up 0.27% over the past day.
